anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ischemic stroke is one of the major causes of morbidity and mortality worldwide. Mitochondria play a vital role in the pathological processes of cerebral ischemic injury, but its transplantation and underlying mechanisms remain unclear. In the present study, we examined the effects of mitochondrial therapy on the modulation of AMPK and SIRT1/PGC-1α signaling pathway, oxidative stress, and NLRP3 inflammasome activation after photothrombotic ischemic stroke (pt-MCAO). The adult male mice were subjected to the pt-MCAO in which the proximal-middle cerebral artery was exposed with a 532-nm laser beam for 4 min by retro-orbital injection of a photosensitive dye (Rose Bengal: 15 mg/kg) before the laser light exposure and isolated mitochondria (100 μg protein) were administered intranasally at 30 min, 24 h, and 48 h following post-stroke. After 72 h, mice were tested for neurobehavioral outcomes and euthanized for infarct volume, brain edema, and molecular analysis. First, we found that mitochondria therapy significantly decreased brain infarct volume and brain edema, improved neurological dysfunction, attenuated ischemic stroke-induced oxidative stress, and neuroinflammation. Second, mitochondria treatment inhibited NLRP3 inflammasome activation. Finally, mitochondria therapy accelerated p-AMPKα(Thr172) and PGC-1α expression and resorted SIRT1 protein expression levels in pt-MCAO mice. In conclusion, our results demonstrate that mitochondria therapy exerts neuroprotective effects by inhibiting oxidative damage and inflammation, mainly dependent on the heightening activation of the AMPK and SIRT1/PGC-1α signaling pathway. Thus, intranasal delivery of mitochondria might be considered a new therapeutic strategy for ischemic stroke treatment.
BACKGROUND: A diet low in fermentable oligo-, di-, monosaccharides and polyols (LFD) improves symptoms in patients with irritable bowel syndrome (IBS). Previous studies have focused on patients with IBS and diarrhea (IBS-D). It is unclear whether LFD is effective for IBS with constipation (IBS-C) or IBS with mixed bowel habits (IBS-M). This open-label, real-world study evaluates the relative effectiveness of the LFD among IBS subtypes.
METHODS: This study analyzes data from a service that provides low-FODMAP meals to individuals with IBS. Participants met with a registered dietitian and completed the IBS symptom severity survey (IBS-SSS) before and after undergoing a 2-4-week period of FODMAP restriction. The primary endpoint was the proportion of participants with ≥50-point decrease in IBS-SSS between the three IBS subtypes.
KEY RESULTS: After FODMAP restriction, 90% of participants with IBS-D, 75% with IBS-C, and 84% with IBS-M met the primary endpoint (p = 0.045). Similar improvement was seen for a 100-point decrease, but the difference between IBS subtypes was not significant (p = 0.46). After FODMAP restriction, all groups had statistically significant improvement in total IBS-SSS as well as individual symptom categories. Improvement in IBS-SSS subcategories was similar among the groups except for the categories of bloating severity (IBS-M had greatest improvement) and bowel movement satisfaction (IBS-C had less improvement).
CONCLUSION & INFERENCES: Though the proportion of responders was highest for IBS-D and lowest for IBS-C, the LFD led to robust improvement in overall symptoms in all IBS subtypes. Key individual symptoms also showed significant improvements in all IBS subtypes.
This group will undertake a routine course of one to one out-patient physiotherapy which will include a BW programme. The BW programme will be prescribed by a physiotherapist and the participant will carry it out, along with other prescribed exercises, in their own home. Each participant will initially be prescribed a 5 minute BW programme to be completed once a day. The length of the BW programme and intensity will be progressed or regressed as deemed appropriate by the treating clinician with the aim for patients to achieve at least 10 minutes of BW every day of the week.
A therapeutic method of reducing or eliminating viral infections in vivo includes subjecting a virally infected patient to one of a variety of strong magnetic fields. A static magnetic field has a magnetic field intensity of at least about 5 nanoTesla sufficient to be effective to disrupt viral metabolism. An alternating magnetic field has a magnetic field intensity of at least 0.1 nanoTesla sufficient to be effective to disrupt viral metabolism. A method of disrupting viral metabolism includes subjecting an infected patient or a mixture of live host cells and virus to the alternating magnetic field. A virus disruption apparatus includes a magnetic field generator of static or alternating magnetic fields. The magnetic field generator is selected from a Magnetic Resonance Imaging device, at least one permanent magnet, at least one superconducting magnet, at least one solenoid, and any combination thereof.
Lower-intensity interventions delivered in primary and community care contacts could provide more equitable and scalable weight management support for postnatal women. This mixed-methods systematic review aimed to explore the effectiveness, implementation, and experiences of lower-intensity weight management support delivered by the non-specialist workforce. We included quantitative and qualitative studies of any design that evaluated a lower-intensity weight management intervention delivered by non-specialist workforce in women up to 5 years post-natal, and where intervention effectiveness (weight-related and/or behavioural outcomes), implementation and/or acceptability were reported. PRISMA guidelines were followed, and the review was prospectively registered on PROSPERO (CRD42022371828). Nine electronic databases were searched to identify literature published between database inception to January 2023. This was supplemented with grey literature searches and citation chaining for all included studies and related reviews (completed June 2023). Screening, data extraction and risk of bias assessments were performed in duplicate. Risk of bias was assessed using the Joanna Briggs Institute appraisal tools. Narrative methods were used to synthesise outcomes. Seven unique studies described in 11 reports were included from the Netherlands (n = 2), and the United Kingdom, Germany, Taiwan, Finland, and the United States (n = 1 each). All studies reported weight-related outcomes; four reported diet; four reported physical activity; four reported intervention implementation and process outcomes; and two reported intervention acceptability and experiences. The longest follow-up was 13-months postnatal. Interventions had mixed effects on weight-related outcomes: three studies reported greater weight reduction and/or lower postnatal weight retention in the intervention group, whereas four found no difference or mixed effects. Most studies reporting physical activity or diet outcomes showed no intervention effect, or mixed effects. Interventions were generally perceived as acceptable by women and care providers, although providers had concerns about translation into routine practice. The main limitations of the review were the limited volume of evidence available, and significant heterogeneity in interventions and outcome reporting which limited meaningful comparisons across studies. There is a need for more intervention studies, including process evaluations, with longer follow-up in the postnatal period to understand the role of primary and community care in supporting women's weight management. Public Health Wales was the primary funder of this review.
Patients in this group will receive pulmonary rehabilitation specified by rehabilitation doctors according to the needs and capacities of each individual, who will attend three times a week for three months. Furthermore, they will receive 4g of citrulline supplementation.
Angioedema involving the extremities, face, lips, mucous membranes, tongue, glottis or larynx has been seen in patients treated with ACE inhibitors, including captopril. If angioedema involves the tongue, glottis or larynx, airway obstruction may occur and be fatal. Emergency therapy, including but not necessarily limited to, subcutaneous administration of a 1:1000 solution of epinephrine should be promptly instituted.

Swelling confined to the face, mucous membranes of the mouth, lips and extremities has usually resolved with discontinuation of captopril; some cases required medical therapy. (see PRECAUTIONS: Information for Patients and ADVERSE REACTIONS.)

Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema (see PRECAUTIONS, Drug Interactions).
PURPOSE:To obtain a hair dye composition capable of exhibiting excellent color fastness to washing of the hair after hair dyeing and imparting sufficient gloss to the dyed hair with extremely rare damage to the hair. CONSTITUTION:A hair dye composition is obtained by blending a quaternary ammonium derivative of a peptide expressed by formula I [at least one of R1 to R3 is average 8-20C alkyl or alkenyl and the rest are 1-3C alkyl, hydroxyalkyl or benzyl; A is 2-3C hydroxyalkylene or alkylene; R4 is amino acid side chain constituting the peptide; (n) is 2-30] as an essential ingredient in an amount of 0.01-10 pts.wt. based on 100 pts.wt. hair dye with other ingredients. The color fastness to washing of the hair after hair dyeing is extremely high and capable of imparting excellent hand feeling such as sufficient gloss and good touch to the hair. Furthermore, the compound expressed by the formula is obtained by reacting a peptide with a compound expressed by formula II to IV (X is Cl, Br, I, NO3, SO4/2, R5OSO3 or R5SO3; R5 is lower alkyl; Y is halogen).
The combined use of gastrointestinal hormones for treating metabolic diseases is gaining increasing attention. The potential of developing novel dual agonists targeting both cholecystokinin 1 (CCK-1) receptor and glucagon-like peptide 1 (GLP-1) receptor to improve the treatment of type 2 diabetes and obesity have not been fully explored. In this investigation, we reported a series of novel GLP-1/CCK-1 receptor co-agonists constructed by linking the C-terminus of a GLP-1 receptor agonist (bullfrog GLP-1) to the N-terminus of a CCK-1 receptor selective agonist NN9056. In comprehensive in vitro assays, these co-agonists exhibited complete agonistic potency on GLP-1 and CCK-1 receptor. Remarkably, 1f displayed superior hypoglycemic and insulinotropic effects when compared to NN9056 and semaglutide. Evaluation in Kunming and diet-induced obesity (DIO) mice unveiled significant acute and enduring hypoglycemic effects of 1f. Administration of 1f to DIO mice resulted in substantial weight loss, normalized lipid metabolism, and enhanced glucose regulation. These preclinical observations strongly advocate for the therapeutic potential CCK-1 and GLP-1 pathways could be harnessed in a single fusion peptide, yielding a promising combination therapy strategy for treating metabolic disorders.
The invention relates to a compound famotidine calcium-magnesium chewable tablet and a preparing method thereof. The compound famotidine calcium-magnesium chewable tablet contains famotidine, calcium carbonate and magnesium hydrate. Specifically, the invention belongs to the medical technical field and relates to a drug combination for treating stomach diseases, in particular to a compound drug containing famotidine, calcium carbonate and magnesium hydrate, and further to a famotidine calcium-magnesium chewable tablet which has excellent pharmacy property and contains famotidine, calcium carbonate and magnesium hydrate. The famotidine calcium-magnesium chewable tablet not only has excellent pharmacy property, but also has excellent chemical stability. The famotidine calcium-magnesium chewable tablet can treat or prevent sour regurgitation, gastric acid excess, heartburn, stomachache, gasteremphraxis, belching and other stomach discomfort clinically. The invention further relates to the preparing method of the famotidine calcium-magnesium chewable tablet.
PROBLEM TO BE SOLVED: To enable to prevent the viral infection of cultured fishes by administering killed bacterium cells to the cultured fishes. SOLUTION: This method for preventing the viral infection of cultured fishes comprises orally administering killed butyric acid bacterium cells to the cultured fishes such as sea bream, young yellowtail, USHIEBI or goldfish. The killed butyric acid bacterium cells are preferably the killed cells of Clostridium butyricum, especially the killed cells of its trophozoite, more preferably the continuously long administrable killed cells of the trophozoite of Clostridium butyricum MIYAIRI (MIYAIRI bacterium). The killed cells can be administered as such or after mixed with a formula feed. The killed cells are mixed with the formula feed in an amount of 10<5> -10<10> cells per 100g of the formula feed, and the mixed formula feed is subsequently fed at a conventional dose.  When administered as such, the killed butyric acid bacterium cells are administered at a dose of 10<4> -10<10> cells per kg of the body weight of the cultured fish. The economical value for reducing an economical loss accompanied by the viral infection of the fishes is large in the fish culture industry.
Model-informed precision dosing of infliximab (intravenously administered) using a Bayesian forecasting software tool. Doses and dosing intervals will be derived from the software tool, aiming to maintain adequate exposure (trough concentration target 5 mg/L).
PURPOSE:To obtain high-purity hemin at a low cost, by hemolyzing erythrocytes, denaturing and precipitating hemoglobin, adjusting the pH, forming hemin- containing precipitates and extracting the precipitates with an acidic organic solvent. CONSTITUTION:Hemin is produced from erythrocytes. In the process, ery throcytes are hemolyzed and the pH of the resultant hemolyzed solution is adjusted to <=6.5 or >=12 to denature hemoglobin. The pH of the above- mentioned hemolyzed solution is adjusted to 7-8 to form hemin-containing precipitates, which are then separated and extracted with an acidic organic solvent, e.g. methanol or acetone, to dissolve the hemin. Precipitates insoluble in the organic solvent, e.g. protein, etc., are removed and acetic acid is added to distil away the organic solvent and recover the hemin. A small amount of the organic solvent used is sufficient, and the solvent distilled away without containing water therein can be reused.
New antibiotics of the mureidomycin group have the formula (see fig. I) wherein X represents the group (see fig. II)       or        (see fig. III) and wherein R represents hydrogen, an alkyl group having from 1 to 10 carbon atoms, an alkenyl group having from 2 to 7 carbon atoms, an alkynyl group having from 3 to 7 carbon atoms, an aryl group having from 6 to 10 carbon atoms, an aralkyl group having from 7 to 10 carbon atoms, or one of the said aryl or aralkyl groups substituted with at least one substituent selected from halogen and alkyl groups having from 1 to 5 carbon atoms.  The compound in which X represents 8-hydroxy-1,2,3,4-tetrahydroisoquinolin-3-yl is named mureidomycin E and the compound in which X represents 6-hydroxy-1,2,3,4-tetrahydroisoquinolin-3-yl is named mureidomycin F.  This group of compounds and their pharmaceutically acceptable esters and salts are useful as antibiotics for the treatment of bacterial infections. Mureidomycins E and F can be obtained by fermentation of a suitable Streptomyces strain, in particular Streptomyces flavidovirens SANK 60486 (BIKOKEN JOHKI 1347:  FERM BP-1347).  ALternatively, all of the compounds can be obtained synthetically by reacting the previously known compound mureidomycin A with an aldehyde of the formula R - CHO.
PROBLEM TO BE SOLVED: To treat infantile hyperstellar cell tumors including brain stem nerve gliocystoma by administrating temozolomide. SOLUTION: Temozolomide of the formula (namely, 3,4-dihydro-3- methyl-4-oxoimidazo-[50,1-d] 1,2,3,4-tetrazine-8-carboximide) is administered. Preferably, the total dose of 50-1,200mg per 1m<2> body surface area of a patient is administered continuously during 5 days. In the case of the total dose 1,000mg/m<2> , a daily dose of 200mg/m<2> is preferably administered for 5 days. Preferably, after a period of 28 days from the first day of the administration temozolomide is repeatedly administered. Otherwise, a smaller amount of dose is administered for a longer period. Preferably, a dose of 75mg/m<2> is administered for 6 to 7 weeks. temozolomide is mixed with anhydrous lactose NF, starch sodium glycolate NF, colloidal silicon dioxide NF, tartaric acid NF and stearic acid NF and can be administered in the form of capsule.
Patients who are never smokers with lung adenocarcinoma and have relapsed after treatment with tyrosine kinase inhibitors (TKIs) will be eligible for enrollment. The trial will proceed in two stages. In the safety lead-in stage, 6 patients will be enrolled and treated with the LP-300 co-administered in combination with carboplatin and pemetrexed. In the absence of any safety signals in these patients, the second stage of the trial protocol will begin. This second stage consists of randomizing patients in a 2:1 allocation ratio to one of two arms: investigational arm of carboplatin, pemetrexed, and LP-300 or the standard of care arm of carboplatin and pemetrexed. Treatment of both groups will be on Day 1 of a 21-day cycle. A total of 4 to 6 treatment cycles are planned (number of cycles determined by PI discretion), with the possibility of patients going into a pemetrexed maintenance phase afterwards.
The purpose of this study was to examine mental health problems and sleep quality among undergraduate students in the post-COVID-19 era, as well as related factors. This cross-sectional study involved 627 undergraduate students from Chiang Mai University in northern Thailand between October and December 2022. Data were collected using a self-administered online questionnaire that included the General Health Questionnaire-12 (GHQ-12), the Center for Epidemiologic Studies-Depression Scale (CES-D), and the Pittsburgh Sleep Quality Index (PSQI). The study found that 57.9% of participants experienced mental health problems (95% CI: 54.0-61.8), 32.2% experienced depression (95% CI: 28.5-35.9), and 68.1% reported poor sleep quality (95% CI: 64.4-71.8). Multiple logistic regression analysis revealed that medical conditions, relationships with family members, relationships with friends or other people, having problems while studying at university, and self-perceived COVID-19 impact score were all associated with mental health problems and poor sleep quality (p < 0.05). Depression was associated with the field of study, relationships with family members, relationships with friends or other people, having problems while studying at university, and self-perceived COVID-19 impact score (p < 0.05). The findings highlight a significant occurrence of poor sleep and mental health issues, including depression, among undergraduate students in the post-COVID-19 era, underscoring the need for ongoing mental health monitoring and interventions to mitigate negative outcomes.
Articles and methods for delivering therapeutic agents to a subject are described. In some cases, these articles and methods may be used to deliver therapeutic agents to the colon of a subject. In some embodiments, the article is configured to release a secretion inducing agent, e.g., to stimulate the release of intestinal fluid. In some embodiments, the article of manufacture comprises a therapeutic agent, such that stimulated intestinal fluid release increases the amount of therapeutic agent available for absorption by the colon. For example, in some embodiments, the articles and methods described herein advantageously promote increased absorption of the therapeutic agent in a subject as compared to a conventionally administered therapeutic agent in the absence of an additional component (e.g., a secretion inducing agent). In some embodiments, the articles and methods described herein can increase colonic motility in a subject. The increased contraction caused by increased motility and increased movement of fluid in the colon may advantageously facilitate dissolution or absorption of the therapeutic agent.
The invention relates to a method for preparing porous starch with high oil absorption rate through preprocessing starch, belonging to the field of starch industry. The method comprises the following steps of: with corn starch as a raw material, preprocessing the raw material, namely size mixing, before enzymolysis, carrying out transient heat-moisture treatment at a temperature near a range of being lower than the gelatinization point, and preparing the porous starch with high oil absorption rate by adopting a complex enzyme method. The prepared porous starch has larger porosity and specific surface area, lower stacking density and favorable oil absorbability and water absorbability; the porous starch can keep remarkable structural integrity in water and other solvents; and the oil absorbability of the porous starch reaches 133.0 percent, and compared with the porous starch prepared without preprocessing, the porous starch prepared by adopting the method disclosed by the invention has the oil absorbability which is increased by 8.0 percent. When the porous starch adsorbed with clove oil is added into a tobacco sheet raw material, the prepared cigarette has remarkably-reduced irritation and dry sensation during smoking. When the porous starch adsorbed with coenzyme Q10 is added into an O/W-type facial cream emulsion, nutrient substances are slowly released and can be sufficiently absorbed by skin when the O/W-type facial cream emulsion is used. The method disclosed by the invention is simple and effective, unnecessary to increase equipment and free of byproducts and has wide application prospect.
Women who are informed about the purpose and practices of the research and who agree to participate in the study voluntarily will not be deviated from routine practices in the hospital. Women who are followed and delivered by the same midwife will be included in the study to ensure that there is no difference between the groups in terms of episiotomy application and birth techniques. When the cervical dilatation is 8 cm, the Birth Comfort Scale will be applied to the pregnant woman, and two hours after the birth, the Birth Satisfaction Scale and the Postpartum Comfort Scale will be applied. Information about the birth process will be recorded in the Birth Information Form.